Company intelligence / Profile preview

Primrose Bio

Ownership: Private
Development stage: Commercial

Overview

Primrose Bio’s platforms have enabled the commercial manufacture of six approved biologic products, including vaccine antigens and recombinant proteins. Their Prima RNApols™ enzymes are available at GMP-grade for clinical and commercial mRNA manufacturing. The Pfenex Expression Technology® is validated in multiple FDA-approved drugs with up to 20x higher yields than traditional systems.

Therapeutic areas: Other
Modalities: Recombinant proteinEnzyme (RNA polymerase)mRNA-based drugs (enabling technology)Vaccine antigens (enabling technology)
Industry: Non-Drug Biotech

Partnerships

MerckJazz PharmaceuticalsAlvogenSerum Institute of IndiaArcellxArcturus TherapeuticsExPLoRNA TherapeuticsIntravacc

Beyond the preview

Go deeper on Primrose Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primrose Bio.

Explore the full profile